This early-phase trial is testing a new radioactive imaging agent called 68Ga-R10602 in 36 people with hormone receptor-positive breast cancer that has come back or spread. The agent is designed to light up tumors on PET/CT scans. The main goals are to check safety and see how we…
Phase: PHASE1 • Sponsor: Radionetics Oncology • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC